Fideuram Intesa Sanpaolo Private Banking S.P.A. Makes New Investment in IDEAYA Biosciences, Inc. $IDYA

Fideuram Intesa Sanpaolo Private Banking S.P.A. bought a new position in shares of IDEAYA Biosciences, Inc. (NASDAQ:IDYA) in the 4th quarter, Holdings Channel.com reports. The institutional investor bought 113,451 shares of the company’s stock, valued at approximately $3,922,000.

A number of other institutional investors and hedge funds also recently modified their holdings of IDYA. Farther Finance Advisors LLC raised its position in shares of IDEAYA Biosciences by 171.1% in the 4th quarter. Farther Finance Advisors LLC now owns 919 shares of the company’s stock valued at $32,000 after acquiring an additional 580 shares during the period. Aster Capital Management DIFC Ltd acquired a new position in IDEAYA Biosciences during the third quarter valued at approximately $38,000. ANTIPODES PARTNERS Ltd increased its stake in IDEAYA Biosciences by 49.4% in the fourth quarter. ANTIPODES PARTNERS Ltd now owns 1,150 shares of the company’s stock valued at $40,000 after purchasing an additional 380 shares in the last quarter. Abich Financial Wealth Management LLC bought a new stake in IDEAYA Biosciences in the third quarter valued at approximately $58,000. Finally, Daiwa Securities Group Inc. raised its holdings in IDEAYA Biosciences by 16.1% in the second quarter. Daiwa Securities Group Inc. now owns 3,141 shares of the company’s stock worth $66,000 after purchasing an additional 436 shares during the period. 98.29% of the stock is owned by institutional investors.

IDEAYA Biosciences Stock Up 4.7%

IDEAYA Biosciences stock opened at $29.65 on Thursday. The stock has a market capitalization of $2.61 billion, a PE ratio of -18.53 and a beta of -0.04. IDEAYA Biosciences, Inc. has a twelve month low of $18.25 and a twelve month high of $39.28. The company has a 50 day moving average of $31.15 and a 200-day moving average of $32.83.

IDEAYA Biosciences (NASDAQ:IDYA) last issued its quarterly earnings data on Tuesday, May 5th. The company reported ($1.11) EPS for the quarter, missing analysts’ consensus estimates of ($1.07) by ($0.04). The company had revenue of $6.56 million for the quarter, compared to analyst estimates of $5.04 million. The firm’s revenue for the quarter was down 39.4% compared to the same quarter last year. During the same quarter last year, the firm posted ($0.82) EPS. Equities analysts anticipate that IDEAYA Biosciences, Inc. will post -4.28 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently weighed in on the stock. Mizuho reduced their price target on shares of IDEAYA Biosciences from $52.00 to $50.00 and set an “outperform” rating on the stock in a research report on Thursday, May 7th. Wedbush raised their price objective on IDEAYA Biosciences from $52.00 to $58.00 and gave the stock an “outperform” rating in a research note on Tuesday, April 14th. Citigroup lifted their target price on IDEAYA Biosciences from $64.00 to $65.00 and gave the stock a “buy” rating in a report on Thursday, February 19th. The Goldman Sachs Group boosted their target price on IDEAYA Biosciences from $31.00 to $35.00 and gave the company a “neutral” rating in a research note on Tuesday, April 14th. Finally, Cantor Fitzgerald restated an “overweight” rating on shares of IDEAYA Biosciences in a report on Wednesday, February 18th. Fifteen analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $50.69.

Insider Transactions at IDEAYA Biosciences

In other news, Director Jeffrey Stein bought 50,000 shares of the stock in a transaction on Monday, March 2nd. The stock was purchased at an average price of $32.96 per share, for a total transaction of $1,648,000.00. Following the acquisition, the director owned 54,281 shares in the company, valued at approximately $1,789,101.76. This trade represents a 1,167.95% increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Company insiders own 4.70% of the company’s stock.

IDEAYA Biosciences Profile

IDEAYA Biosciences is a clinical-stage precision oncology company dedicated to the discovery and development of novel therapies that exploit synthetic lethality in cancer cells. By targeting key DNA damage response pathways, the company aims to selectively kill tumor cells exhibiting specific genetic vulnerabilities while sparing healthy tissue. IDEAYA’s pipeline includes small-molecule inhibitors designed to address underserved tumor types, and its lead programs are advancing through Phase 1 and Phase 2 clinical trials in multiple oncology indications.

Central to IDEAYA’s approach is its Modular Approach to Precision (MAP) platform, which integrates proprietary genomic and functional screening technologies to identify critical cancer-specific dependencies.